Overall Very Good news, but SHs want action into tangible outcome. Coming months and coming weeks should be replaced with a tentative deadline. Deadline may be updated as and when required in a legitimate manner.
It reminds of what Michelle Miller, so called ceo has been telling and announcing since 2018 statistical significance data. Discussion in progress, ......, so question arises about the outcome? Why was Becker recruited? Was Becker recruted to bake biotron bread? Becker failed miserably by mentioning not home run!
Michelle Miller, Biotron’s Managing Director, said: “We are delighted to be partnering with C14. Martina and her team have a long track record in assisting companies such as Biotron to achieve commercialisation of clinical and preclinical assets as well as platform technologies. Their involvement allows us to leverage internal expertise in a cost-effective, efficient manner. With data from the recent clinical trials in hand, together with supporting preclinical and scientific data that demonstrate the potential utility of Biotron’s unique approach to treating serious viral infections, the Company is now focused on achieving licencing or partnerships with its antiviral portfolio.”
That mentioend, SHs wants regular unambiguous updates. MM and PN must Not get any payrise until deal done and SP is north of at least $0.46/s. Next CR should at least at $0.16/s
Good news, but is is too early to give MM ad PN any incentives.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)